A decade-long study of 55,000 cancer patients adds to mounting evidence that anemia drugs such as Amgen's Epogen and Johnson & Johnson's Procrit boost the risk of blood clots significantly. Report [1]
A decade-long study of 55,000 cancer patients adds to mounting evidence that anemia drugs such as Amgen's Epogen and Johnson & Johnson's Procrit boost the risk of blood clots significantly. Report [1]
Links:
[1] http://www.reuters.com/article/rbssHealthcareNews/idUSN1032780720091110